ARTBIO is a company focused on radioligand therapy (RLT) for cancer treatment. Their approach is patient-centric and holistic, with a deep understanding of cancer biology and the infrastructure for therapy design, manufacture, and distribution.

ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Omega Funds

F-Prime Capital

Third Rock Ventures

We are #hiring across a variety of roles in CMC, Quality and Clinical to bring our #alpha #radioligand #therapies to patients. 

Check out ARTBIO's open positions and feel free to get in touch.

https://lnkd.in/eKK7vxdz 

Daniel Rossetto Jordi Vall-llossera ✪ Philippe Dasse ✪ ☤ Emanuele Ostuni

Thank you Richard Zimmermann for including ARTBIO in this helpful overview recently published in The Journal of Nuclear Medicine - JNM. 

This editorial discusses the potential of #Pb212 as an ideal #isotope for #alpha #radioligand #therapy based on its ability to overcome challenges seen with other isotopes in the #radiopharmaceutical space. Its many ideal properties include precursor supply, a short half-life, a high energy deposition into tumors and a potentially lower environmental footprint. 

Learn more about how we are leveraging Pb212 in our approach: https://lnkd.in/emDFdbTY 
 
 #nuclearmedicine #biotech

Such a privilege for ARTBIO to present our vision for leveraging AlphaDirect and 212-Pb as a potential game changer in radioligand therapy at JPM24!  2024 is going to be a really exciting year for us; especially the clinical advancement of our lead PSMA asset, AB001. Extremely proud of Emanuele Ostuni, the ARTBIO team, the ingenuity of our founders and tenacity our dedicated investors to support our mission to be the Leader in Lead!

#JPMHC24 #radiopharmaceuticals

COM:ARTBIO

ARTBIO

Financials Not Available